PPARG and bladder transitional cell carcinoma: For BLCA in the high-Siglec15 group, targeted therapy such as blocking Siglec15, β-catenin, PPAR-γ, and FGFR3 pathways and anti-angiogenic therapy may be valuable alternative options.